Prospective, single-arm, multi-centre, open-label study to investigate the potential to reduce concomitant antipsychotics use in patients with moderate to severe dementia of Alzheimer's type (DAT) treated with memantine.

Trial Profile

Prospective, single-arm, multi-centre, open-label study to investigate the potential to reduce concomitant antipsychotics use in patients with moderate to severe dementia of Alzheimer's type (DAT) treated with memantine.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 23 Sep 2011

At a glance

  • Drugs Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Therapeutic Use
  • Sponsors Merz Pharmaceuticals GmbH
  • Most Recent Events

    • 12 Sep 2011 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 12 Sep 2011 Primary endpoint identified as dose arameters, and visual analogue scale as reported by ClinicalTrials.gov.
    • 12 Sep 2011 Actual end date changed from Sep 2009 to June 2009 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top